

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Compl t If Known Application Number <u>09706540 10/226,366</u> Filing Date <u>November 4, 2000 12/3/2003</u> First Named Inventor <u>Soto-Jara, C.</u> Group Art Unit <u>1647</u> Examiner Name <u>Bunner, B.E.</u> Attorney Docket Number <u>009621-34567 DIV</u>	
Sheet	1	of	1

[illegible][illegible]

Examiner Signature	Bridget E. Dunner	Date Considered	11/10/2005
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

PTO/SB/08A (10-01)



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	To be assigned 1647
Examiner Name	To be assigned B. Bunner
Attorney Docket Number	3154-6317 2115

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BBB	-	FADESSI et al. Beta-Sheet Breaker Strategy for the Treatment of Alzheimer's Disease. Drug Development Res 56(2): 184-193, 2002.	-
BBB	-	BLONDELLE et al. Polyalanine-based Peptides as Models for Self-Associated Beta-Pleated-Sheet Complexes. Biochemistry 36: 8393-8400, 1997.	-
		European Search Report, EP 00 97 6928, dated September 10, 2004.	
BBB	-	FAUCHERE et al., "Evaluation of the Stability of Peptides and Pseudopeptides as a Tool in Peptide Drug Design," Advances in Drug Research, 1992, pp. 127-159, vol. 23.	-
	-	GANTE, Joachim, "Peptidomimetics--Tailored Enzyme Inhibitors," Angewandte Chemie, 16 September 1994, pp. 1699-1720, vol. 33, no. 17.	-
	-	GOLABEK et al. The Interaction Between Apolipoprotein E and Alzheimer's Amyloid Beta-Peptide is Dependent on Beta-Peptide Conformation. J Biol Chem 271(18): 10602-10606, 1996.	-
	-	HETENYI et al. Computational Studies on the Binding of the Beta-Sheet Breaker (BSB) Peptides on Amyloid BetaA(1-42). J Molec Structure 542: 25-31, 2001.	-
	-	PERMANNE et al. Reduction of Amyloid Load and Cerebral Damage in a Transgenic Mouse Model of Alzheimer's Disease by Treatment with a Beta-Sheet Breaker Peptide. Faseb J. 16(8):860-862, 2002.	-
	-	PODUSLO et al., "Beta-Sheet Breaker Peptide Inhibitor of Alzheimer's Amyloidogenesis with Increased Blood-Brain Barrier Permeability and Resistance to Proteolytic Degradation in Plasma," Journal of Neurobiology, 5 June 1999, pp. 371-382, vol. 39, no. 3.	-
	-	SIGURDSSON et al. In vivo Reversal of Amyloid-Beta Lesions in the Rat Brain. J Neuropath Exp Neurol 59(1): 11-17, 2000	-
	-	SOTO et al. Inhibition of Alzheimer's Amyloidosis by Peptides that Prevent Beta-Sheet Conformation. Biochem Biophys Res Commun. 226(3): 672-680, 1996	-
BBB	-	SOTO et al., "Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in a Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy," Nature Medicine, July 1998, pp. 822-826, vol. 4, no. 7.	-

Examiner Signature	Bridget E. Bunner	Date Considered	11/10/05
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	To be assigned 1647
Examiner Name	To be assigned B. Bunner
Attorney Docket Number	3154-6317 211S

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BEB	-	SOTO, Claudio, "Alzheimer's and Prion Disease as Disorders of Protein Conformation Implications for the Design of Novel Therapeutic Approaches," Journal of Molecular Medicine, May 1999, pp. 412-418, vol. 77 no. 5.	-
	-	SOTO, Claudio. Beta-Amyloid Disrupting Drugs. CNS Drugs 12(5): 347-356, 1999.	-
	-	SOTO, Claudio. Plaque Busters: Strategies to Inhibit Amyloid Formation in Alzheimer's Disease. Mol Med Today. 5(8):343-350, 1999.	-
BEB	-	WOOD et al. Prolines and Amyloidogenicity in Fragments of the Alzheimer's Peptide Beta/A4. Biochemistry 34:724-730, 1995.	-

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/706,540

Filed: November 4, 2000

Patent No: 6,689,753

Issue Date: February 20, 2004

For: B SHEET BREAKER PEPTIDE ANALOGS THAT INHIBIT B PLEATED SHEET FORMATION IN AMYLOID B -PEPTIDE, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned B. Bunner
Attorney Docket Number	3154-6317.2US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
BEB	-	US-5,051,185	09-24-1991	Watanabe et al.	
	-	US- 5,216,127	06-01-1993	Hirai et al.	
	-	US- 5,230,996	07-27-1993	Rath et al.	
	-	US- 5,276,059	01-04-1994	Caughey et al.	
	-	US- 5,278,189	01-11-1994	Rath et al.	
	-	US- 5,449,663	09-12-1995	Bicher	
	-	US- 5,589,154	12-31-1996	Anderson	
	-	US- 5,824,908	04-29-1997	Bicher	
	-	US- 5,650,418	07-22-1997	Rath et al.	
	-	US- 5,700,447	12-23-1997	Bucala et al.	
	-	US- 5,733,524	03-31-1998	Bucala et al.	
	-	US- 5,733,933	03-31-1998	Bucala et al.	
	-	US- 5,780,615	07-14-1998	Bucala et al.	
	-	US- 5,801,200	09-01-1998	Bucala et al.	
	-	US- 5,869,534	02-09-1999	Bucala et al.	
	-	US- 5,935,927	08-10-1999	Vitek et al.	
	-	US- 5,958,883	09-28-1999	Snow	
	-	US- 6,001,331	12-14-1999	Caprathe et al.	
	-	US- 6,034,211	03-07-2000	Kelly	
BEB	-	US- 6,037,327	03-14-2000	Castillo et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		DE 193 35 902 A1	02-26-1990	Intec Imundiagnostika GmbH		
BEB		0 234 051	09-02-1987	Stichting Centraal Laboratorium		
		0 319 144 A1	06-07-1989	Asahi Kasei Kogyo Kabushiki Kaisha		
		0 494 848 A1	07-15-1992	Kabi Pharmacia AB		
		EP 1 130 031 A1	09-05-2001	Universitair Medisch Centrum Utrecht		
		EP 1 179 588 A1	02-13-2002	Matsumoto		
		WO 91/18610	12-12-1991	Olle Ljungqvist Medical AB		
BEB		WO 91/19488	12-26-1991	Rath et al.		

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

11/18/05

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned B. Burner
Attorney Docket Number	3154-6317.2US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
BFB	-	US- 6,037,458	03-14-2000	Hirai et al.	
	-	US- 6,136,548	10-24-2000	Anderson	
	-	US- 6,340,783 B1	01-22-2002	Snow	
	-	US- 6,399,314 B1	06-04-2002	Krishnamurthy	
	-	US- 6,410,598 B1	06-25-2002	Vitek et al.	
	-	US- 6,436,969 B1	08-20-2002	Khalifah et al.	
	-	US- 6,462,171 B1	10-08-2002	Soto-Jara et al.	
	-	US- 6,471,960 B1	10-29-2002	Anderson	
	-	US- 2002/0133019 A1	09-19-2002	Klunk et al.	
	-	US- 2002/0187157 A1	12-12-2002	Jensen et al.	
	-	US- 2003/0017995 A1	01-23-2003	Khalifah et al.	
	-	US- 2003/0050245 A1	03-13-2003	Gebbink et al.	
	-	US- 6,537,969 B1	03-25-2003	Blass	
	-	US- 2003/0072770 A1	04-17-2003	McAnalley et al.	
	-	US- 2003/0086938 A1	05-08-2003	Jensen et al.	
	-	US- 2003/0087407 A1	05-08-2003	Soto-Jara et al.	
	-	US- 2003/0109435 A1	06-12-2003	Prenner et al.	
	-	US- 2003/0118593 A1	06-26-2003	Dan et al.	
	-	US- 2003/0176365 A1	09-18-2003	Blass	
BFB	-	US- 2003/0236391 A1	12-25-2003	Klunk et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
BFB	-	WO 92/11847	07-23-1992	Kabi Pharmacia AB		
	-	WO 94/01116	01-20-1994	The Government of the United States		
	-	WO 94/28909	12-22-1994	Bicher		
	-	WO 95/20979	08-10-1995	Picower Institute for Medical Research		
	-	WO 96/15799	05-30-1996	Rutgers, The State University of New Jersey		
	-	WO 96/39834	12-19-1996	New York University		
	-	WO 97/26919	07-31-1997	Warner-Lambert Company		
	-	WO 97/46547	12-11-1997	Texas A & M University System		
BFB	-	WO 98/06418	02-19-1998	Mannatech, Inc.		

Examiner
Signature

Bridget E. Burner

Date
Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

11/18/05

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3

of

4

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned B. Bunner
Attorney Docket Number	3154-6317.2US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	Country Code ³	Number ⁴ - Kind Code ⁵ (if known)				
B02		WO 99/02545	01-21-1999	Novopharm Biotech Inc.		
		WO 99/09999	03-04-1999	University of Washington		
		WO 99/21565	05-06-1999	Cornell Research Foundation, Inc.		
		WO 00/59493	10-12-2000	Kansas University Medical Center		
		WO 00/66717	11-09-2000	Matsumoto		
		WO 00/68263	11-16-2000	Neurochem, Inc.		
		WO 01/07474 A1	02-01-2001	Stott		
		WO 01/12598 A2	02-22-2001	Trustees of Columbia University		
		WO 01/50134 A2	07-12-2001	American Cyanamid Co.		
		WO 01/58476 A2	08-16-2001	European Molecular Biology Laboratory		
		WO 01/62284 A2	08-30-2001	M & E Biotech A/S		
		WO 01/62799 A2	08-30-2001	Universitair Medisch Centrum Utrecht		
		WO 02/16333 A2	02-28-2002	University of Pittsburgh		
		WO 03/006893 A2	01-23-2003	Elan Pharmaceuticals, Inc.		
B02		WO 2004/004698 A2	01-15-2004	Universitair Medisch Centrum Utrecht		

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	4	of	4
-------	---	----	---

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	To be assigned B. Dunner
Attorney Docket Number	3154-6317.21US

NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

Bridget C. Banner


Date
Considered

11/10/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/726,366
Filing Date	December 3, 2003
First Named Inventor	Claudio Soto-Jara
Group Art Unit	1647
Examiner Name	B. Bunner
Attorney Docket Number	3154-6317.2US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
Bob	-	US- 5,137,873	08-11-1992	Yankner	-
Bob	-	US- 6,689,753	02-10-2004	Soto-Jara	-
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
Bob	-	WO 96/28471	09-19-1996	Pharmaceutical Peptides Incorporated	-	-
	-	WO 02/04954 A2	01-17-2002	Applied Research Systems ARS Holding N.V.	-	-
	-	WO 03/050139 A2	06-19-2003	Applied Research Systems ARS Holding N.V.	-	-
	-	WO 2004/005336 A2	01-15-2004	Applied Research Systems ARS Holding N.V.	-	-
	-	WO 2004/050689 A2	06-17-2004	Applied Research Systems ARS Holding N.V.	-	-
	-	WO 2004/083243 A1	09-30-2004	Applied Research Systems ARS Holding N.V.	-	-
	-	WO 2004/096845 A2	11-11-2004	Applied Research Systems ARS Holding N.V.	-	-
Bob	-	WO 2004/111652 A1	12-23-2004	Applied Research Systems ARS Holding N.V.	-	-

Examiner
Signature

Bridget E. Bunner

Date
Considered

11/10/05

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/23/05

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/726,366
		Filing Date	December 3, 2003
		First Named Inventor	Claudio Soto-Jara
		Group Art Unit	1647
		Examiner Name	B. Bunner
Sheet 2 of 3	Attorney Docket Number	3154-6317.2US	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
EBB	-	BURGESS et al., Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue, The Journal of Cell Biology, 1990, pp. 2129-38, Vol. 111.	-
	-	DOBELL et al., A Biotechnological Method Provides Access to Aggregation Competent Monomeric Alzheimer's 1-42 Residue Amyloid Peptide, Biotechnology, September 13, 1995, pp. 988-93, Vol. 13.	-
	-	FRASER et al., Conformation and Fibrillogenesis of Alzheimer A β Peptides with Selected Substitution of Charged Residues, J. Mol. Biol. 1994, pp. 64-73, Vol. 244.	-
	-	GHISO et al., Unifying Features of Systemic and Cerebral Amyloidosis, Molecular Neurobiology, 1994, pp. 49-64, Vol. 8, No. 1.	-
	-	HILBICH et al., Substitutions of Hydrophobic Amino-Acids Reduce the Amyloidogenicity of Alzheimers-Disease Beta-A4 Peptides, Journal of Molecular Biology, November 20, 1992, Vol. 228, No. 2. (abstract)	-
	-	KELLY et al., Alternative conformations of amyloidogenic proteins govern their behavior, 1996, pp. 11-17, Vol. 6.	-
	-	LAZAR et al., Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Molecular and Cellular Biology, Mar. 1988, pp. 1247-52, Vol. 8, No. 3.	-
	-	MERLINI et al., Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: Inhibition of amyloidogenesis, Proc. Natl. Acad. Sci., March 1995, pp. 2959-2963, Vol. 92, USA.	-
	-	PIKE et al., Structure-Activity Analyses of β -Amyloid Peptides: Contributions of the β 25-35 Region to Aggregation and Neurotoxicity, Journal of Neurochemistry, January 1995, pp. 253-65, Vol. 64, No. 1.	-
EBB	-	RUDINGER, Characteristics of the amino acids as components of a peptide hormone sequence, Jun. 1976, pp 1-7, In Peptide Hormones, Parsons (ed.), University Park Press, Baltimore.	-

Examiner Signature	Bridget E. Bunner	Date Considered	11/10/05
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

8/23/05

PTO/SB/08B(10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/726,366
		Filing Date	December 3, 2003
		First Named Inventor	Claudio Soto-Jara
		Group Art Unit	1647
		Examiner Name	B. Bunner
		Attorney Docket Number	3154-6317.2US
Sheet	3	of	3

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BEB	-	SOTO et al., Abstract, Structural Determinants of the Alzheimers Amyloid Beta-Peptide, Journal of Neurochemistry, 1994, pp. 1191-98, Vol. 63.	-
	-	SOTO et al., Abstract, Two Conformational States of Amyloid Beta-Peptide - Implications for the Pathogenesis of Alzheimers-Disease, February 17, 1995, pp. 115-18, Vol. 186.	-
	-	SOTO et al., Fibrillogenesis of synthetic amyloid- β peptides is dependent on their initial secondary structure, Neuroscience Letters 200, 1995, pp. 105-08.	-
	-	SOTO et al., Inhibition of Alzheimer's Amyloidogenesis by Anti- β -sheet Peptides, <i>Alzheimer's Disease: Biology, Diagnosis and Therapeutics</i> , 1996, pp. 711-16.	-
	-	SOTO et al., The α -Helical to β -Strand Transition in the Amino-terminal Fragment of the Amyloid β -Peptide Modulates Amyloid Formation, The Journal of Biological Chemistry, 1995, pp. 3063-3067, Vol. 270, No. 7.	-
	-	TOMIYAMA et al., Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid β Protein in Vitro, Biochemical and Biophysical Research Communications, October 14, 1994, pp. 76-83, Vol. 204, No. 1.	-
	-	WILLE et al., Abstract, Prion protein amyloid: Separation of scrapie infectivity from PrP polymers, 1996, pp. 181-201, Vol. 199.	-
BEB	-	WISNIEWSKI et al., Peptides Homologous to the Amyloid Protein of Alzheimer's Disease containing a Glutamine for Glutamic acid substitution have Accelerated Amyloid Fibril Formation, Biochemical and Biophysical Research Communications, September 30, 1991, pp. 1247-54, Vol. 179, No. 3.	-

Examiner Signature	Bridget E. Bunner	Date Considered	11/10/05
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

*Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231: DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.